* Note: Prices are in Million (M) USD.
Description:
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $72 M
Debt : $7 M
EBITDA : $18 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $18 M
Average Revenue: $112 M
Revenue Converted To Free Cash Flow (%): 16%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 82.66%
Since Free Cash Flow (FCF) to Revenue percentage is greater than 15, 3 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $167 M
Revenue 4 Years Ago (2020-12-31): $186 M
Last 5 Years Average Revenue Growth: -2%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $18 M
Share Count 5 Years Ago (2020-12-31): $16 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 70%
Since Average ROE is greater than 20, 5 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $159
52-Week Low: $90
Threshold Price (15% Above 52-Week Low): $104
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $2,621 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 23 points to above Ligand Pharmaceuticals Incorporated (LGND) stock.
Last 11 Years Avg PE 24.8, Fair Value PE 25, Industry Based PE 20, RCFC Based PE 15.9. Based on these 4 values, average assigned is 21.43.
The fair value of Ligand Pharmaceuticals Incorporated (LGND) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
